EmbeddingGemma 2: an open, lightweight multimodal embedding model
deepmind.google·6d ago
AI Engineering
Hacker News·Aug 15·5 min read
AI in drug discovery — what it is, where we stand and the path forward
TL;DR
AI's role in drug discovery has grown, yet its clinical impact remains limited. Key challenges include insufficient focus on real-world applications and lengthy operationalization processes.
✦ Why It Matters
Focus on improving AI model development to enhance clinical relevance in drug discovery today.
Key Takeaways
- Shift focus from model validation to decision-making improvement.
- Enhance problem definitions for better AI model applicability.
- Prioritize clinical translation during AI model development.
- Increase accessibility of AI tools for drug discovery.
Full Summary
Over the past decade, artificial intelligence (AI) has gained traction in drug discovery, aiming to expedite the development of safer and more effective medications. Despite the emergence of various AI methodologies, their actual clinical relevance has been disappointing, with few demonstrating significant impact.
Challenges include a lack of emphasis on clinical translation during model development, difficulties in applying AI to complex life science data, and poorly defined problems leading to inadequate computational models. The article suggests that a shift from merely validating AI models to assessing their ability to enhance decision-making is crucial.
Recommendations for improving AI's translational relevance in drug discovery are provided, emphasizing the need for better benchmarking studies and operationalizing AI tools for broader accessibility.